ArticleCellular oncology (Dordrecht, Netherlands)2026
SREBP2-RAB11A-ZDHHC20 axis orchestrates FGFR3 palmitoylation and membrane retention to drive bladder cancer progression.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundNon-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of all bladder cancer cases and is characterized by a high recurrence rate, requiring long-term surveillance and repeated treatments that impose substantial clinical burdens. While aberrant fibroblast growth factor receptor 3 (FGFR3) signaling is a well-established driver in the majority of NMIBC cases, the precise molecular mechanisms regulating FGFR3 plasma membrane stability and trafficking remain poorly defined, limiting targeted therapeutic development. This study aims to elucidate the molecular pathway sustaining FGFR3 at the plasma membrane and its clinical relevance.
methodsRAB11A expression was analyzed in NMIBC datasets and correlated with survival. In FGFR3-high RT4 cells, RAB11A was knocked down to assess effects on proliferation, apoptosis, and FGFR3 membrane localization via functional assays and immunoblotting. Mechanistic interactions were examined through co-immunoprecipitation and promoter-reporter assays. A phase-separation-defective SREBP2 mutant (F178A) was used to validate transcriptional activation. In vivo tumor growth and FGFR3 membrane localization were evaluated in xenograft models following RAB11A or ZDHHC20 knockdown. Statistical analyses included Student’s t-test and log-rank test.
resultsRAB11A was significantly up-regulated in NMIBC, correlated with FGFR3 mRNA expression, and predicted poorer recurrence-free survival. RAB11A knockdown suppressed proliferation, induced apoptosis, and reduced membrane FGFR3 without altering transcript levels. RAB11A acted as a scaffold recruiting ZDHHC20 to promote FGFR3 palmitoylation and inhibit FGFR3 degradation. SREBP2 directly activated RAB11A transcription, dependent on its liquid–liquid phase separation capability. In vivo, knockdown of RAB11A or ZDHHC20 attenuated tumor growth and reduced membrane FGFR3.
conclusionsWe identify a novel SREBP2-RAB11A-ZDHHC20 axis essential for FGFR3 palmitoylation, membrane retention, and oncogenic signaling in NMIBC. Targeting this pathway may offer a therapeutic strategy for FGFR3-driven bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.